Nanobiotix is trading 5.93% up at $33.40 after final Phase 1 melanoma data announced October 24 and presented at ESMO. - Among 24 heavily pretreated patients, the study reported a 41.7% response rate, including four complete responses, and median overall survival of 17.8 months. - Findings were preliminary and warrant further evaluation in randomized trials. - Shares had already gained 7.39% to close at $31.53 on October 26; no separate October 27 company announcement was found.